Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
- First Posted Date
- 2024-12-18
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 55
- Registration Number
- NCT06739122
- Locations
- 🇺🇸
D&H Tamarac Research Center, LLC, Tamarac, Florida, United States
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
- Conditions
- Interventions
- First Posted Date
- 2024-12-06
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 58
- Registration Number
- NCT06721013
- Locations
- 🇺🇸
MedStar Georgetown University Hospital, Washington, District of Columbia, United States
A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy Participants
- First Posted Date
- 2024-12-05
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 48
- Registration Number
- NCT06719128
- Locations
- 🇺🇸
Orange County Research Center, Lake Forest, California, United States
🇺🇸Clinical Pharmacology of Miami, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
A Study of LY4060874 in Healthy Participants
- First Posted Date
- 2024-11-29
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 132
- Registration Number
- NCT06709820
- Locations
- 🇺🇸
Fortrea, Inc., Dallas, Texas, United States
🇸🇬Lilly Centre for Clinical Pharmacology, Singapore, Singapore
A Drug-Drug Interaction Study of Orforglipron (LY3502970) with Quinidine in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 28
- Registration Number
- NCT06704763
- Locations
- 🇺🇸
ICON, Salt Lake City, Utah, United States
A Study of Orforglipron (LY3502970) to Compare a Single Capsule and Multiple Capsules in Healthy Participants
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 80
- Registration Number
- NCT06692348
A Study of LY4005130 in Healthy Participants
- First Posted Date
- 2024-11-15
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 140
- Registration Number
- NCT06690996
- Locations
- 🇺🇸
Fortrea Clinical Research Unit, Dallas, Texas, United States
A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 275
- Registration Number
- NCT06683508
- Locations
- 🇺🇸
The Institute for Liver Health II dba Arizona Clinical Trials - Mesa, Chandler, Arizona, United States
🇺🇸Stamford Therapeutics Consortium, Stamford, Connecticut, United States
🇺🇸Northeast Research Institute (NERI), Fleming Island, Florida, United States
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 125
- Registration Number
- NCT06672939
- Locations
- 🇺🇸
MedPharmics, LLC, Gulfport, Mississippi, United States
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 125
- Registration Number
- NCT06672549
- Locations
- 🇺🇸
Ann and Robert Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸Velocity Clinical Research, Omaha, Nebraska, United States
🇺🇸Vanderbilt Health One Hundred Oaks, Nashville, Tennessee, United States